{
    "clinical_study": {
        "@rank": "109225", 
        "arm_group": [
            {
                "arm_group_label": "Roflumilast", 
                "arm_group_type": "Experimental", 
                "description": "Dermal 0.5% Roflumilast cream, topically, twice daily for up to 15 days."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Roflumilast placebo-matching cream, topically, twice daily for up to 15 days."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the effect of topical roflumilast on the reduction\n      of atopic dermatitis lesions in adults with atopic dermatitis."
        }, 
        "brief_title": "Topical Roflumilast in Adults With Atopic Dermatitis", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": "Atopic Dermatitis", 
        "condition_browse": {
            "mesh_term": [
                "Dermatitis", 
                "Dermatitis, Atopic"
            ]
        }, 
        "detailed_description": {
            "textblock": "The drug being tested in this study is called roflumilast. Roflumilast is being tested to\n      treat people who have atopic dermatitis. This study will look at the skin lesions of people\n      who take topical roflumilast compared with a cream with no active ingredient.\n\n      The study will enroll approximately 40 patients. Participants will be randomly assigned (by\n      chance, like flipping a coin) to one of the two treatment groups\u2014which will remain\n      undisclosed to the patient and study doctor during the study (unless there is an urgent\n      medical need):\n\n        -  Dermal 0.5% Roflumilast cream\n\n        -  Placebo (dummy inactive cream) - this is a cream that looks like the study drug but has\n           no active ingredient\n\n      All participants will be asked to apply the cream twice a day throughout the study.\n\n      This multi-center trial will be conducted at 3 sites in Germany. The overall time to\n      participate in this study is 7 weeks. Participants will make 6 visits to the clinic."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female between 18 to 65 years of age, inclusive, with atopic dermatitis (AD)\n             meeting Hanifin and Rajka's criteria\n\n          2. Presence of lesional skin areas of moderate severity characterized by modified local\n             SCORing Atopic Dermatitis (SCORAD) of at least 4, with an erythema score \u22652, and\n             confirmed by a qualified investigator\n\n          3. Must have an index/target lesion of moderate in severity of approximately 20 cm^2,\n             suitable for topical treatment\n\n          4. Must be willing to wash out from AD current active therapy prior to entry in the\n             study\n\n          5. Is willing and able to apply the study medication as directed, comply with study\n             instructions and commit to all follow-up visits for the duration of the study.\n\n          6. A male who is nonsterilized and sexually active with a female partner of childbearing\n             potential agrees to use adequate contraception from signing of informed consent\n             throughout the duration of the study and for 12 weeks after last dose.\n\n          7. A female of childbearing potential who is sexually active with a nonsterilized male\n             partner agrees to use routinely adequate contraception from signing of informed\n             consent throughout the duration of the study and for 12 weeks after last dose.\n\n          8. In the opinion of the investigator, the participant is capable of understanding and\n             complying with protocol requirements.\n\n          9. The participant or, when applicable, the participant's legally acceptable\n             representative signs and dates a written, informed consent form and any required\n             privacy authorization prior to the initiation of any study procedures.\n\n        Exclusion Criteria:\n\n          1. Has received any investigational compound within 30 days, or within 5 half-lives of\n             the compound (whichever is the longer) prior to the Screening visit.\n\n          2. Have a history of AD unresponsive or poorly responsive to topical treatments.\n\n          3. Has a history of hypersensitivity to phosphodiesterase (PDE)-4 inhibitors or to drugs\n             of similar chemical classes or any inactive ingredients of the trial medication.\n\n          4. Has, in the judgment of the investigator, clinically significant abnormal\n             hematological parameters of hemoglobin, hematocrit, or erythrocytes at Screening.\n\n          5. Has a history or current clinically relevant allergies or idiosyncrasy to drugs or\n             food.\n\n          6. Has extensive exposure to ultraviolet (UV) light in the 4 weeks prior to first\n             application of study medication, including tanning and sun beds or is intending to\n             have such exposure during the study treatment that may interfere with the study\n             assessments as judged by the investigator.\n\n          7. Evidence of oozing of target lesion.\n\n          8. Has a current skin complication such as erythroderma or overt bacterial or viral\n             infection for which treatment with anti-infectives are indicated.\n\n          9. Has systemic treatment with corticosteroids or retinoids for studied condition within\n             3 months prior to the first application of study medication.\n\n         10. Had topical or transdermal treatments, such as but not limited to retinoids, nicotine\n             or hormone replacement therapies, on or near the intended site of application within\n             4 weeks prior to first application of study medication.\n\n         11. Treatment with systemic/locally acting medications/procedures which might counter or\n             influence the study aim within 4 weeks prior to first application of study medication\n             and during the study (eg, anti-histamines) .\n\n         12. Has used emollients/moisturizers on areas to be treated within 24 hours prior to the\n             first application of study medication.\n\n         13. Has used biologics at any time for treatment of AD.\n\n         14. Is currently enrolled in an investigational drug or device study.\n\n         15. Any clinically significant illness that may influence the outcome of the trial 4\n             weeks before Day 1 and during the trial.\n\n         16. Has alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) values\n             greater than 2.0 \u00d7 upper limit of normal (ULN), or other clinically significant\n             abnormal laboratory test that, in the opinion of the Investigator, would compromise\n             the participant's ability to safely complete the trial.\n\n         17. Has a significant medical condition and/or conditions that, in the opinion of the\n             Investigator, would interfere with the treatment, safety or compliance with the\n             protocol.\n\n         18. Has a history of infection with hepatitis B, hepatitis C, or human immunodeficiency\n             virus.\n\n         19. Has a history of alcoholism or illicit drug abuse within 5 years prior to the\n             Screening Visit or is currently consuming >14 alcoholic drinks per week.\n\n         20. If female, is pregnant, nursing or planning a pregnancy during the study period.\n\n         21. Has a history of cancer that has not been in remission for at least 5 years prior to\n             the first dose of study medication. This criterion does not apply to those\n             participants with successfully resected basal cell or stage I squamous cell carcinoma\n             of the skin.\n\n         22. Has chronic or clinically relevant acute infections.\n\n         23. Has a history of depression associated with suicidal ideation and behavior.\n\n         24. Has hemodynamically significant cardiac arrhythmias or heart valve deformations.\n\n         25. Is an immediate family member, study site employee, or is in a dependent relationship\n             with a study site employee who is involved in conduct of this study (eg, spouse,\n             parent, child, sibling) or may consent under duress."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01856764", 
            "org_study_id": "ROF-DERM_203", 
            "secondary_id": [
                "2012-003000-12", 
                "U1111-1133-6455"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Roflumilast", 
                "description": "Roflumilast cream", 
                "intervention_name": "Roflumilast", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Roflumilast placebo-matching cream", 
                "intervention_name": "Roflumilast placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Phosphodiesterase 4 Inhibitors"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Drug therapy", 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gera", 
                        "country": "Germany"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Grosshansdorf", 
                        "country": "Germany"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hannover", 
                        "country": "Germany"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mainz", 
                        "country": "Germany"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Schwerin", 
                        "country": "Germany"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Budapest", 
                        "country": "Hungary"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nyiregyhaza", 
                        "country": "Hungary"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Szarvas", 
                        "country": "Hungary"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Torokbalint", 
                        "country": "Hungary"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bloemfontein", 
                        "country": "South Africa"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cape Town", 
                        "country": "South Africa"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pretoria", 
                        "country": "South Africa"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Germany", 
                "Hungary", 
                "South Africa"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2a, 15-Day, Randomized, Parallel Group, Double-Blind, Multi-Centre, Vehicle Controlled Trial to Assess the Efficacy and Local Safety of a Cream Containing 0.5% Roflumilast - a Phosphodiesterase Type 4 Inhibitor (PDE4i) Dermal Formulation - on Atopic Dermatitis Patients With Skin Lesions of Moderate Severity", 
        "overall_official": {
            "affiliation": "Takeda", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The modified local SCORAD intensity scale represents one part of the SCORAD index, which is a severity scoring system for atopic dermatitis. The symptoms erythema, edema/papulation, oozing/crusts, excoriations, and lichenification of the target lesion will be assessed by the investigator and the intensity of each of the criteria will be graded according to the following 4-point scale: 0 = absent; 1 = mild; 2 = moderate; 3 = severe. Worst scores indicate greater level of severity.", 
            "measure": "Change from Baseline to Day 15 in modified local SCORing Atopic Dermatitis (SCORAD)", 
            "safety_issue": "No", 
            "time_frame": "Baseline and Day 15"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01856764"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Diffusion of water through the skin (the TEWL) will be measured using a Tewameter at Baseline and on Day 15.", 
                "measure": "Change from Baseline to Day 15 in transepidermal water loss (TEWL) values", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 15"
            }, 
            {
                "description": "The severity of each symptom in the target lesion during the last 24 h will be assessed by the participants using a numeric scale with a range from 0 to 10, where 0 indicates the absence of the symptoms and 10 indicates the most severe symptoms.", 
                "measure": "Change from baseline to Day 15 in participants' assessment of pruritus", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 15"
            }
        ], 
        "source": "Takeda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}